Rasagiline Mesylate

Rasagiline Mesylate is a new MAO-B inhibitor for the treatment of idiopathic Parkinson's disease. (In Vitro) :Rasagiline (0.25 nM; 96 hours) significantly increases the proliferation rates of SH-SY5Y and 1242-MG upon Dexamethasone (10 μM) treatment. (In Vivo) :Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Motor behavioural tests show improvements in motor deficits associated with 2.5 mg/kg Rasagiline therapy.